Class information for:
Level 1: INTERACTION CONDITION//TARGETED CLINICAL TRIALS//INFLUENCE CONDITION

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
22290 330 34.4 75%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
970 10197 CAUSAL INFERENCE//PRINCIPAL STRATIFICATION//STATISTICS IN MEDICINE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 INTERACTION CONDITION Author keyword 4 75% 1% 3
2 TARGETED CLINICAL TRIALS Author keyword 4 75% 1% 3
3 INFLUENCE CONDITION Author keyword 3 100% 1% 3
4 YU HUANG DING HOSP Address 3 45% 2% 5
5 PRECISION CANCER MEDICINE Author keyword 2 67% 1% 2
6 TAILORED THERAPEUTICS Author keyword 2 67% 1% 2
7 COMPANION DIAGNOSTIC DEVICE Author keyword 1 100% 1% 2
8 DIAGNOST DEVICES BRANCH Address 1 50% 1% 2
9 INDIVIDUALIZED CANCER THERAPY Author keyword 1 50% 1% 2
10 ENRICHMENT DESIGN Author keyword 1 29% 1% 4

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class		 LCSH search Wikipedia search
1 INTERACTION CONDITION 4 75% 1% 3 Search INTERACTION+CONDITION Search INTERACTION+CONDITION
2 TARGETED CLINICAL TRIALS 4 75% 1% 3 Search TARGETED+CLINICAL+TRIALS Search TARGETED+CLINICAL+TRIALS
3 INFLUENCE CONDITION 3 100% 1% 3 Search INFLUENCE+CONDITION Search INFLUENCE+CONDITION
4 PRECISION CANCER MEDICINE 2 67% 1% 2 Search PRECISION+CANCER+MEDICINE Search PRECISION+CANCER+MEDICINE
5 TAILORED THERAPEUTICS 2 67% 1% 2 Search TAILORED+THERAPEUTICS Search TAILORED+THERAPEUTICS
6 COMPANION DIAGNOSTIC DEVICE 1 100% 1% 2 Search COMPANION+DIAGNOSTIC+DEVICE Search COMPANION+DIAGNOSTIC+DEVICE
7 INDIVIDUALIZED CANCER THERAPY 1 50% 1% 2 Search INDIVIDUALIZED+CANCER+THERAPY Search INDIVIDUALIZED+CANCER+THERAPY
8 ENRICHMENT DESIGN 1 29% 1% 4 Search ENRICHMENT+DESIGN Search ENRICHMENT+DESIGN
9 REMARK 1 30% 1% 3 Search REMARK Search REMARK
10 ALPHA ALLOCATION 1 40% 1% 2 Search ALPHA+ALLOCATION Search ALPHA+ALLOCATION

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ADAPTIVE SIGNATURE DESIGN 27 78% 5% 18
2 PREDICTIVE BIOMARKER VALIDATION 8 100% 2% 5
3 OMICS BASED PREDICTORS 6 71% 2% 5
4 CLINICAL TRIAL DESIGNS 5 27% 5% 17
5 SIGNATURE DESIGN 4 75% 1% 3
6 PREDICTIVE BIOMARKERS 3 23% 4% 13
7 SELECTING 1 2 67% 1% 2
8 TRIAL DESIGNS 2 33% 2% 5
9 QUALITY BRISQ 1 50% 1% 2
10 ADAPTIVE RANDOMIZATION 1 40% 1% 2

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Biomarker enrichment strategies: matching trial design to biomarker credentials 2014 12 40 35%
The national biomarker development alliance: confronting the poor productivity of biomarker research and development 2015 1 23 35%
Genome Medicine in Cancer: What's in a Name? 2015 1 6 33%
Designing Transformative Clinical Trials in the Cancer Genome Era 2013 42 30 23%
Trial Designs for Personalizing Cancer Care: A Systematic Review and Classification 2013 10 75 61%
Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers 2015 1 59 29%
Integrating biomarkers in clinical trials 2011 29 71 37%
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology 2010 37 26 42%
Clinical trial designs for predictive marker validation in cancer treatment trials 2005 225 15 27%
US FDA and personalized medicine: in vitro diagnostic regulatory perspective 2010 10 10 50%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 YU HUANG DING HOSP 3 45% 1.5% 5
2 DIAGNOST DEVICES BRANCH 1 50% 0.6% 2
3 CANC DIAGNOSIS PROGRAM 1 27% 0.9% 3
4 COMPLEX AD T SYST INITIAT 1 27% 0.9% 3
5 CANC DIAG PROGRAM 1 12% 2.1% 7
6 BIOSTAT BIONFORMAT 1 50% 0.3% 1
7 BUSINESS INNOVAT UNIT 1 50% 0.3% 1
8 CANC DHHSNIH 1 50% 0.3% 1
9 CANC DIAGNOST PROGRAM 1 50% 0.3% 1
10 CLIN BIOMARKER GRP 1 50% 0.3% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000195146 ADAPTIVE TREATMENT STRATEGIES//DYNAMIC TREATMENT REGIME//DYNAMIC TREATMENT REGIMES
2 0.0000186493 PHARMACOGENOMICS//PERSONALIZED MEDICINE//PROGRAM PERSONALIZED MED TARGETED THER EUT
3 0.0000155174 CONDITIONAL POWER//INTERIM ANALYSIS//SAMPLE SIZE RE ESTIMATION
4 0.0000138712 SURROGATE ENDPOINT//PRENTICE CRITERION//PRENTICE CRITERIA
5 0.0000120219 BRIDGING STUDY//MULTIREGIONAL CLINICAL TRIAL//MULTIREGIONAL TRIAL
6 0.0000085202 ONCOTYPE DX//TRIPLE NEGATIVE BREAST CANCER//TRIPLE NEGATIVE
7 0.0000083959 CONTINUAL REASSESSMENT METHOD//DOSE FINDING//DOSE FINDING STUDIES
8 0.0000082810 EVOLUT CANC//PETOS PARADOX//TRANSLAT CANC THER EUT
9 0.0000078790 TUFTS CTSI//EXPLAINED VARIATION//FRACTIONAL POLYNOMIALS
10 0.0000074058 RESPONSE ADAPTIVE DESIGN//DOUBLY ADAPTIVE BIASED COIN DESIGN//RESPONSE ADAPTIVE DESIGNS